Bristol Myers lines up a date with the FDA to expand the footprint of its $13B heart drug
In April, Bristol Myers Squibb won approval for mavacamten, now marketed as Camzyos, to improve symptoms of obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle becomes too thick and blocks blood flow.
Friday morning, Bristol Myers announced that its filing for mavacamten in an additional indication in a subset of patients with oHCM had been accepted by the FDA. The new filing centers on the group of patients who have severe symptoms and are referred to septal reduction therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.